Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $99.29.
A number of equities analysts recently weighed in on DXCM shares. Oppenheimer lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Sanford C. Bernstein boosted their price objective on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Royal Bank of Canada lowered their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Citigroup boosted their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th.
Insider Transactions at DexCom
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. Principal Securities Inc. grew its position in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after purchasing an additional 135 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in shares of DexCom by 4.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after buying an additional 162 shares during the period. Crossmark Global Holdings Inc. grew its holdings in shares of DexCom by 1.0% during the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after buying an additional 182 shares during the last quarter. GPS Wealth Strategies Group LLC increased its position in DexCom by 13.2% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after acquiring an additional 185 shares during the period. Finally, Peterson Wealth Services raised its stake in DexCom by 7.1% during the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock valued at $236,000 after acquiring an additional 201 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.
DexCom Trading Down 0.9 %
Shares of DXCM stock opened at $86.83 on Friday. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The firm has a market cap of $33.92 billion, a PE ratio of 51.99, a price-to-earnings-growth ratio of 2.22 and a beta of 1.12. The company has a 50-day moving average of $80.77 and a two-hundred day moving average of $76.21. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles
- Five stocks we like better than DexCom
- Earnings Per Share Calculator: How to Calculate EPS
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Following Congress Stock Trades
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- The Basics of Support and Resistance
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.